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Levuglandin (LG) E2, a cytotoxic seco prostanoic acid
co-generated with prostaglandins by nonenzymatic re-
arrangements of the cyclooxygenase-derived endoper-
oxide, prostaglandin H2, avidly binds to proteins. That
LGE2-protein adducts can also be generated nonenzy-
matically is demonstrated by their production during
free radical-induced oxidation of low density lipopro-
tein (LDL). Like oxidized LDL, LGE2-LDL, but not native
LDL, undergoes receptor-mediated uptake and im-
paired processing by macrophage cells. Since radical-
induced lipid oxidation produces isomers of prosta-
glandins, isoprostanes (isoPs), via endoperoxide
intermediates, we postulated previously that a similar
family of LG isomers, isoLGs, is cogenerated with isoPs.
Now iso[4]LGE2-protein epitopes produced by radical-
induced oxidation of arachidonic acid in the presence of
protein were detected with an enzyme-linked immu-
nosorbent assay. Iso[4]LGE2-protein epitopes are also
generated during free radical-induced oxidation of LDL.
All of the LGE2 isomers generated upon oxidation of
LDL are efficiently sequestered by covalent adduction
with LDL-based amino groups. The potent electrophilic
reactivity of iso-LGs can be anticipated to have biologi-
cal consequences beyond their obvious potential as
markers for specific arachidonate-derived protein mod-
ifications that may be of value for the quantitative as-
sessment of oxidative injury.
Oxidative modification of low density lipoprotein (LDL)1 is
considered a key step in the etiology of atherosclerosis (1, 2).
Free radical-induced oxidation of LDL consumes polyunsatu-
rated fatty esters and concomitanty generates lipid-derived
electrophiles which modify LDL by covalent adduction with
protein-based nucleophiles (3–5). Receptor recognition of the
resulting protein modifications leads to uptake of the oxidized
(ox) LDL by macrophages (6–8). Because uptake is unregu-
lated and processing of oxLDL is inefficient, the macrophages
become lipid-laden foam cells, progenitors of atherosclerotic
plaques (9). To acquire a fundamental molecular level under-
standing of atherogenesis and other biological sequelae of oxi-
dative injury, we are identifying the chemical structures of
lipid oxidation products that bind with proteins.
Previously, we discovered derivatives of levulinaldehyde
with prostaglandin side chains appended at the carbons a and
b to the aldehyde group. Named levuglandins (10), e.g. LGE2
(Fig. 1), these seco prostanoic acids are cogenerated with pros-
taglandins (PGs) (11–13) by rearrangements of the endoperox-
ide PGH2 which occur readily (t1⁄2 5 5 min at 37 °C) under the
conditions of its cyclooxygenase (COX)-promoted biosynthesis
from arachidonic acid (AA). LGE2 binds avidly with proteins
(14) forming a protein-bound pyrrole, LGE2-pyrrole (15), as
well as protein-protein (16, 17) and DNA-protein (18) cross-
links. We recently reported mass spectral characterization of
several lysine-based modifications that are generated by cova-
lent adduction of LGE2 with proteins (19).
2 Levels of LGE2-
protein adducts are markedly elevated in the blood of athero-
sclerosis and end stage renal disease patients versus healthy
controls (21). Furthermore, LGE2-modified LDL is recognized
by macrophages, taken up, and inefficiently processed in close
analogy and competition with oxLDL (8). In effect, LGE2-mod-
ified LDL may function as a Trojan horse, fostering uptake but
then compromising the ability of macrophage proteases to hy-
drolyze oxidatively damaged LDL protein.
Because COX only converts free AA into PGH2, this pathway
is regulated by enzymatic release of AA from AA-PC (22, 23). In
contrast, a free radical pathway oxidizes AA-PC directly to
produce phospholipid endoperoxides (24–26). We previously
showed that LGE2-protein adducts are also produced during
free radical-induced oxidation of LDL (27). While the enzymatic
pathway generates a single stereoisomer with trans disposed
side chains, peroxy radical cyclization generates an isomeric
mixture in which stereoisomers with cis disposed side chains
predominate (28) as, for example, in the 2-lysophosphatidyl-
choline (PC) ester 8-epi-PGH2-PC (Fig. 1). Rearrangement of
8-epi-PGH2-PC would deliver 8-epi-LGE2-PC. However, be-
cause the stereocenters at positions 8 and 9 are lost during
Paal-Knorr condensation (29) of this LG-phospholipid with ly-
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syl amino groups of LDL protein, formation of a pyrrole adduct
in conjunction with enzyme-catalyzed hydrolytic release of ly-
sophosphatidylcholine (30–32) generates the same LGE2-pyr-
role as that formed by the cyclooxygenase pathway (Fig. 1).
Mouse peritoneal macrophages internalize and degrade
LGE2-LDL if the molar ratio of LGE2 to LDL protein (apoB)
exceeds a threshold somewhere between 10:1 and 38:1 by a
receptor mediated uptake that is completely inhibited by ox-
LDL (8). Furthermore, uptake of oxLDL is inhibited by LGE2-
LDL, supporting the conclusion that both LGE2-LDL and ox-
LDL are recognized by the same receptor. However, the ratio of
LGE2 to apoB in oxLDL does not exceed 2:1. Nevertheless, the
total modification of apoB by all of the isomeric levulinaldehyde
derivatives produced by oxidation of AA might suffice to ac-
count for receptor recognition, uptake, and inefficient process-
ing of oxLDL. Thus, because hydrogen atom abstraction readily
occurs nonregioselectively at any doubly allylic methylene, we
postulated that the free radical pathway not only can produce
a stereoisomeric mixture of levulinaldehyde derivatives with
PG side chains, i.e. iso-LGs, but also structurally isomeric
levulinaldehyde derivatives with nonprostanoid side chains,
i.e. iso[n]LGs. For example, hydrogen atom abstraction from
the 10-position of AA-PC followed by cyclization of an intermediate
8-peroxyeicosatetraenoyl radical could lead to iso[4]PGH2-PC and
then iso[4]LGE2-PC (Fig. 1), where the number in brackets signi-
fies the length of the carboxylic side chain appended to a common
2,3-dioxabicyclo[2.2.1]heptane or levulinaldehyde core. The gener-
ation of phospholipid endoperoxides that are structural isomers of
PGH2 by free radical-induced oxidation was postulated previously
to account for the formation of isoprostanes (24, 25). Thus,
iso[4]PGH2-PC (12-H2-IsoP) is also the putative precursor of iso-
prostanes that have been designated 12-F2-IsoP, 12-E2-IsoP, and
12-D2-IsoP (33). In analogy with the chemistry of LGE2, we ex-
pected that iso[4]LGE2-PC would form iso[4]LGE2-pyrrole by cova-
lent adduction to proteins and concomitant phospholipolysis (Fig.
1). We now report confirmation of this hypothesis. Thus, the gen-
eration of iso[4]LGE2-protein epitopes during in vitro nonenzy-
matic free radical-induced oxidation of LDL was detected with an
immunoassay using antibodies raised against an iso[4]LGE2-pro-
tein adduct. Since iso[4]LGE2 is formed by the isoprostane pathway
but not by the COX pathway, the new antibody allows unambigu-
ous assessment of the formation of iso-LGs from the isoprostane
pathway. In a companion paper (19), we report mass spectral char-
acterization of the covalent iso-LG-derived protein modifications
that are generated during free-radical induced oxidation of LDL.
EXPERIMENTAL PROCEDURES
General Methods
Centrifugation was done on a Sorvall centrifuge at 5 °C and 2000
rpm. Absorbance values of enzyme-linked immunosorbent assays
(ELISAs) were measured on a Bio-Rad Microplate Reader using dual
wavelength (405 nm to read the plate and 650 nm as a reference).
Materials
Spectrapor membrane tubing (Mr cutoff 14,000 number 2) for dialysis
was obtained from Fisher Scientific Co. The following commercially
available materials were used as received: AA, docosahexaenioc acid
(DHA), eicosapentaenoic acid (EPA), eicosatrienoic acid (ETA), g-lino-
lenic acid (g-LA), linoleic acid (LA), chicken egg ovalbumin (CEO, grade
V, 99%), bovine serum albumin (BSA, fraction V, 96–99%), human
serum albumin (HSA, fraction V), and disodium p-nitrophenyl phos-
phate, were from Sigma; keyhole limpet hemocyanin (KLH, ICN
Biochemicals); goat anti-rabbit IgG-alkaline phosphatase (Roche Mo-
lecular Biochemicals): p-(N,N-dimethylamino)benzaldehyde (DMAB,
Aldrich, WI). Phosphate-buffered saline (PBS) was prepared from a pH
7.4 stock solution containing 0.2 M NaH2PO4/Na2HPO4, 3.0 M NaCl, and
0.02% NaN3 (w/w). This solution was diluted 20 times as needed. LGE2
(34), iso[4]LGE2 (35), and 4-oxopentanal-BSA (36) were prepared as
described previously. LDL was isolated (37) from human plasma and
oxidized in vitro to give oxLDL as described previously (27). HNE-HSA,
NaCNBH3-reduced HNE-HSA, and MDA-HSA were prepared as de-
scribed previously (38). ON-KLH antibodies (36) and LGE2-KLH anti-
bodies (27) were prepared as described previously.
Iso[4]LGE2-KLH Antigen
A PBS solution containing 3.1 mM iso[4]LGE2 (1.3 mg, 3.69 mmol)
and 1.5 mM KLH (9.84 mg, 7.96 mg/ml, 4.92 mmol of lysyl residues) was
incubated at room temperature for 1 h. The solution was then dialyzed
FIG. 1. Cyclooxygenase (enzymatic)
pathway and free radical-induced
(nonenzymatic) route to LGs and iso-
LGs via rearrangements of endoper-
oxide intermediates.
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against PBS (3 3 1 liters over 60 h) at room temperature. After dialysis,
the final volume of the solution was adjusted to 5 ml. The final protein
concentration, 1.25 mg/ml, was determined by the Pierce bicinchoninic
acid (BCA) protein assay (39) using solutions of BSA as standards.
Ehrlich Pyrrole Assay of Iso[4]LGE2-Protein Adducts
An Ehrlich pyrrole assay (40, 41) was performed to determine the
concentration of protein-bound iso[4]LGE2-derived pyrroles as de-
scribed previously for determining the concentration of LGE2-derived
pyrroles (15, 27). Tritium-labeled LGE2-HSA and LGE2-BSA were used
as a standards for the assay. The amount of LGE2 bound to HSA or BSA
was determined by quantitative radiochemical analysis. The data for
the standards (Fig. 2) fits the equation: [pyrrole (mmol)] 5 2.22 (absorb-
ance at 586 nm). The absorption maximum (lmax) for LGE2-HSA-de-
rived and iso[4]LGE2-BSA-derived Ehrlich pyrrole assay chromophores
were 586 and 584 nm, respectively. The concentration of pyrrole was
presumed to be equal to the concentration of LGE2 that is bound to BSA
or HSA. This assumes a quantitative yield of protein-bound LGE2-
derived pyrrole. Thus, the concentration of pyrrole estimated by Ehrlich
assay is an upper limit for protein-bound iso[4]LGE2-derived pyrrole.
The pyrrole concentration in the iso[4]LGE2-KLH solution is 0.52 mM
KLH-bound iso[4]LGE2.
Iso[4]LGE2-BSA Coating Agent
A PBS solution containing 4.54 mM iso[4]LGE2 (1.6 mg, 4.54 mmol)
and 0.2 mM BSA (13.2 mg, 11.7 mmol of lysyl residues) was incubated at
37 °C for 12 h. The solution was then dialyzed against PBS (4 3 500 ml)
over 48 h at room temperature. After dialysis, the final volume of the
solution was adjusted to 6 ml. The final protein concentration, deter-
mined using the Pierce BCA protein assay as described above, was 1.85
mg/ml. The pyrrole concentration, 0.59 mM BSA-bound iso[4]LGE2, was
determined by an Ehrlich assay using LGE2-BSA and LGE2-HSA as
standards.
Iso[4]LGE2-HSA Standard
A PBS solution containing 3.55 mM iso[4]LGE2 (2.5 mg, 7.10 mmol)
and 0.16 mM HSA (20.6 mg, 18.30 mmol of lysyl residues) was incubated
at 37 °C for 16 h. The solution was then dialyzed against PBS (3 3 1
liters) for 48 h at room temperature. The final volume of the solution
was adjusted to 10 ml. The final protein concentration, determined
using Pierce BCA protein assay as described above, was 1.81 mg/ml.
The pyrrole concentration, 0.52 mM HSA-bound iso[4]LGE2, was deter-
mined by Ehrlich assay using LGE2-BSA and LGE2-HSA as standards.
Immunization
The immunogen, iso[4]LGE2-KLH (5.0 mg) containing 0.75 mmol of
iso[4]LGE2 per mg of KLH, was diluted to 5 ml with pH 7.4 PBS. An
aliquot (500 ml) was emulsified in Freund’s complete adjuvant (500 ml).
Each of two Pasturella free, New Zealand White rabbits (Hazelton)
were inoculated intradermally into several sites on the back (200 ml)
and rear leg (200 ml). Booster injections of iso[4]LGE2-KLH with
Freund’s incomplete adjuvant were given every 21 days. Antibody titer
was monitored 10 days after each inoculation by ELISA as described
below.
Antibody Purification
The iso[4]LGE2-KLH immune serum from the 73 day bleeding of
rabbit 1, containing 34.4 mg/ml protein, as determined by absorbance at
280 nm (A280 5 1.35 for 1.0 mg/ml), was purified using a protein G
column as described previously (21). The resulting antibody solution
(8.75 ml) contained 1.47 mg/ml purified IgGs. This corresponded to
13.3% of the total protein in the immune serum.
ELISA
For all ELISAs, unless otherwise noted, duplicates of each sample
were run on the same plate.
Antibody Titers—For determination of antibody levels in rabbit blood
serum, iso[4]LGE2-BSA containing 10 mol of pyrrole/mol of protein, was
used as coating agent. The iso[4]LGE2-BSA conjugate (100 ml of a
solution containing 4.4 mg/ml in pH 7.4 PBS) was added to each well of
a sterilized Baxter ELISA plate. The plate was then incubated at 37 °C
for 1 h in a moist chamber. After discarding the coating solution, each
well was washed with PBS (3 3 300 ml), then filled with 1.0% CEO in
PBS (300 ml), and incubated at 37 °C for 1 h to block remaining active
sites on the plastic phase. Each well was washed with 0.1% CEO in PBS
(300 mL) and then 100 ml of rabbit serum from each bleeding diluted
1:10,000 with 0.2% CEO in PBS, or 0.2% CEO in PBS without serum for
a blank, was dispensed into the sample wells. Normal rabbit, i.e. prior
to inoculation with antigen, serum diluted as above was employed as a
negative response control. The ELISA was completed as described pre-
viously (21). The antibody titer rose abruptly after 3 weeks, reaching a
plateau within about 30 days (Fig. 3).
Competitive Antibody Binding Inhibition Studies—For antibody
binding inhibition studies to measure cross-reactivities, an iso[4]LGE2-
BSA adduct was used as coating agent and iso[4]LGE2-HSA was used
as a standard. On each ELISA plate, a blank, a positive control con-
taining no inhibitor, and up to 10 serial dilutions of each inhibitor and
the iso[4]LGE2-HSA standard were run. The standard was prepared by
diluting a 1.04 mM HSA-bound iso[4]LGE2 solution in PBS to 104 mM
with pH 7.4 PBS. A serial dilution of factor 0.2 was used. Each well of
the plate was coated with iso[4]LGE2-BSA solution (100 ml), prepared
by diluting a solution containing 1.08 mM BSA-bound iso[4]LGE2 in
PBS to 432 nM with pH 7.4 PBS. The plate was covered with a plastic
lid and placed in incubator at 37 °C for 1 h, and then allowed to come to
room temperature. After discarding the supernatant, each well was
washed with pH 7.4 PBS (3 3 300 ml) and then blocked by incubating
1 h at 37 °C with 300 ml of 1% CEO in pH 7.4 PBS. After coming to room
temperature, the supernatant was discarded and the wells rinsed with
0.1% CEO in pH 7.4 PBS (300 ml). For each sample and the iso[4]LGE2-
HSA standard, the undiluted sample solution (150 ml) and aliquots (150
ml) of up to nine 1:10 serial dilutions with 5 mM pH 7.4 PBS were
incubated in test tubes at 37 °C for 1 h with antibody solution (150 ml)
that was prepared by adding the required amount of protein G column
purified antibody (0.294 mg/ml) in pH 7.4 PBS to 0.2% CEO in pH 7.4
PBS (2.8 ml/14 ml of 2% CEO). The remaining ELISA procedure and
similar antibody binding inhibition studies with LGE2-KLH antibody,
LGE2-BSA adduct as coating agent, and LGE2-HSA as standard were
performed as described previously (21).
Cross-reactivity of LGE2-Lysine Lactam and Hydroxylactam—A mix-
ture of LGE2-lysine lactam and hydroxylactam adducts was obtained by
incubating LGE2 with [
3H]lysine (27,00 cpm/mg) under argon overnight
at 37 °C. The mixture was applied to a C18 SepPak cartridge (Waters)
that had been preconditioned with methanol (5 ml) and water (10 ml).
The SepPak was washed with heptane (10 ml) and heptane/ethyl ace-
tate (1:1, v/v, 10 ml) before elution with methanol/ethyl acetate (2:3, v/v,
10 ml). The eluate was dried, resuspended in 10% aqueous methanol,
and subjected to HPLC (4.6 3 250 mm Macrosphere 300 C18 column
FIG. 2. The correlation between LGE2-bound to absorbance at
586 nm for the Ehrlich pyrrole assay, using DMAB and HCl, of
LGE2-protein adducts: LGE2-BSA (l) and LGE2-HSA (M).
FIG. 3. Antibody titer against iso[4]LGE2-KLH (1:10,000
dilution).
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from Alltech; 10 min in 0.1% aqueous acetic acid, then 30% acetonitrile
in 0.1% aqueous acetic acid; 1 ml/min). Fractions (1 ml) were collected
and aliquots subjected to scintillation counting. Aliquots of fractions
exhibiting UV absorbance at 205 nm (Fig. 4A) and containing radioac-
tivity, which indicates the incorporation of lysine, were assessed by
LC/MS (Fig. 4, B and C) by direct infusion using a Finnigan TSQ7000
spectrometer with the sheath gas held at 70 p.s.i., auxiliary gas at
10 p.s.i., and with 25 volts on the capillary, a capillary temperature of
220 °C, and the tube lens voltage at 90 V. Fractions deemed to contain
only compounds with the molecular ion of the lactam (m/z 479.4) or
hydroxylactam (m/z 495.4) adducts and were combined. None of these
fractions contained detectable amounts of the LGE2-derived pyrrole
which would show [MH]1 5 463, [M 1 H 2 H2O]
1 5 445, or [M 1 Na]1
5 485. The resulting mixture of lactam and hydroxylactam adducts was
again analyzed by LC/MS, revealing no contamination by compounds
with the molecular ion of the pyrrole adduct (m/z 463). The putative
lactam and hydroxylactam adducts were also subjected to collision-
induced dissociation, which resulted in fragmentation patterns consist-
ent with the structures assigned to the compounds (19). A sample
containing 50 ng each of LGE2-lysine lactam and hydroxylactam was
dissolved in PBS/EtOH (75 ml, 4:1, v/v) to give 140 pmol/well as final
concentration. LGE2-BSA was used as coating agent and LGE2-HSA
was used as standard to measure cross-reactivity. The ELISA was done
as under “Competitive Antibody Binding Inhibition Studies.”
Autoxidation of Polyunsaturated Fatty Acids (PUFAs) in the Presence
of HSA—Fatty acid (2 mg) and HSA (30 mg, 0.45 mmol) were dissolved
in 0.1 M PBS (10 ml). Autoxidation was started by addition of 20 mM
sodium ascorbate (510 ml) and 0.8 mM FeSO4z7H2O (510 ml) (42). The
solutions were incubated at 37 °C for 24 h under air. After incubation
the reaction was quenched by adding 1 mM EDTA (200 ml) to each
solution which then was dialyzed against pH 7.4 PBS (2 3 2 liters) for
40 h at room temperature. Samples of PUFAs that had been oxidized in
the presence of HSA were analyzed for LGE2-, iso[4]LGE2-, and HNE-
derived epitopes by ELISAs using LGE2-KLH (27), iso[4]LGE2-KLH, or
ON-KLH (36) antibodies, respectively, in pH 7.4 PBS containing 0.001%
TweenTM 20 and 0.2% CEO.
LGE2- and Iso[4]LGE2-Protein Immunoreactivity in OxLDL—ELISA
of oxLDL was performed the same as the inhibition assays, except a
dilution factor of 0.3 was employed. The starting concentration was the
undiluted samples. The time dependence of appearance of protein-
bound LGE2- and iso[4]LGE2-derived epitopes during oxidation of LDL
was determined as described in our previous study of LGE2-pyrrole
generation during oxidation of LDL (27).
Trapping ELISA Detection of Free LGE2—To detect any free LGE2
that may be released upon oxidation of LDL, a trapping ELISA was
done on the ultrafiltrate from oxLDL. Thus, LDL (0.5 mg/ml) was
dialyzed at 5 °C for 5 h against pH 7.4 PBS (4 liters), and then for 12 h
against fresh buffer (4 liters). The LDL was then incubated at 37 °C
with 10 mM CuSO4. The reaction product mixture was then filtered
using an Ultrafree-CL filter unit (NMWL: 10,000) for 3 h in a Beck-
mann centrifuge at 5 °C and 4,000 rpm. Each well of a microtiter plate
was coated with 100 ml of BSA (1 mg/ml) in pH 7.4 PBS and was
incubated at 37 °C for 1 h. Following washing once with PBS, samples
for a standard curve containing LGE2 (0–35 pmol/well), or the filtrate
from oxLDL were added to the wells (100 ml/well). After incubation for
3 h at 37 °C followed by washing once with PBS, each well was filled
with 300 ml of 1% CEO for 1 h at 37 °C. After washing once with 0.1%
CEO, 100 ml of KLH-LGE2 antibody was added to each well and the
plate was gently shaken for 1 h at room temperature. After three
washes with 0.1% CEO, 100 ml/well of goat anti-rabbit IgG-alkaline
phosphatase (1:1,000) was added and the mixture was incubated for 1 h
at room temperature. After washing three times with 0.1% CEO, 100 ml
of disodium p-nitrophenyl phosphate (10 mg) in water (11 ml, pH
adjusted to 9.6 using NaOH) containing glycine (50 mM) and MgCl2 (1
mM) were added and the resulting mixture was incubated for about 20
min at room temperature. The reaction was terminated by adding 3 M
NaOH (50 ml) to each well, and the absorbance was read at 405 nm on
a micro-ELISA plate reader. A standard curve, constructed from ab-
sorbance data for solutions containing 0–35 pmol/well of LGE2 (Fig. 5)
showed a linear increase in absorbance with LGE2 concentration in the
standard solutions. No absorbance was observed for any of the wells
treated with ultrafiltrate from oxLDL.
RESULTS
Synthesis of Iso[4]LGE2-protein Adducts—Iso[4]LGE2 is a
chemically sensitive vinylogous b-hydroxy aldehyde that was
freshly prepared for reaction with proteins (BSA, HSA, and
KLH) to afford iso[4]LGE2-protein adducts. We previously
showed that for high LGE2/protein ratios, Paal-Knorr conden-
sation of LGE2 with e-amino groups of lysyl residues of proteins
gives mainly LGE2-derived protein-bound pyrrole (21). Earlier
studies also demonstrated that quantitative analysis of LGE2-
derived protein-bound pyrroles can be accomplished using the
Ehrlich assay that measures the absorbance of a blue-green
chromophore generated by the condensation of LGE2-pyrrole
with DMAB (15).
For the present study, iso[4]LGE2-protein adducts, rich in
iso[4]LGE2-pyrrole, were prepared by exposing various pro-
teins to an excess of iso[4]LGE2. The levels of protein-bound
iso[4]LGE2-derived pyrrole in these adducts were determined
FIG. 4. Analysis of LGE2-lysine lactam and hydroxylactam ad-
ducts. A, LGE2-lysine adducts collected from solid phase extraction on
a C18 Sep-Pak cartridge (Waters) were subjected to reverse phase
HPLC. Compounds exhibiting absorbance at 205 nm were analyzed by
LC/MS. Peaks corresponding to hydroxylactam adducts are labeled H
and those corresponding to lactam adducts are labeled L. A typical mass
spectrum of a hydroxylactam adduct is shown in B and contains the
protonated molecular ion as well as ions resulting from sodium adduc-
tion and dehydration that occurs in the mass spectrometer. A typical
spectrum of a lactam adduct is shown in C; it also displays ions corre-
sponding to the molecular ion of the LGE2-lysine lactam as well as ions
resulting from sodium adduction and dehydration.
FIG. 5. A standard curve for LGE2 in an LGE2-trapping ELISA.
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by Ehrlich assays (40, 41) using LGE2-protein adducts as
standards since the availability of radiolabeled LGE2 allowed
an accurate independent assessment of LGE2 content in these
standard samples. As expected, the chromophore generated by
the condensation of iso[4]LGE2-pyrrole with DMAB is very
similar to that from LGE2-pyrrole. Thus, the absorption max-
ima (lmax) observed for the LGE2-HSA-DMAB and iso[4]LGE2-
BSA-DMAB chromophores are 586 and 584 nm, respectively. It
is reasonable to presume that the structurally similar Ehrlich
chromophore derived from an iso[4]LGE2-pyrrole has the same
extinction coefficient as that derived from an LGE2-pyrrole.
A linear correlation was obtained for a plot of pyrrole con-
centration verses absorbance at 586 nm for the DMAB chro-
mophore of LGE2-derived protein-bound pyrroles in LGE2-BSA
and LGE2-HSA (see Fig. 2). The concentration of LGE2-derived
protein-bound pyrrole in LGE2-HSA was taken to be equal to
the total amount of protein-bound LGE2 (0–500 nmol/sample)
as determined by quantitative radiochemical analysis. This
assumes a quantitative yield for pyrrole formation. Therefore,
the use of LGE2-protein-derived pyrrole as a standard for the
Ehrlich assay provides an upper limit for the concentration of
iso[4]LGE2-protein-derived pyrrole. The final protein concen-
trations in iso[4]LGE2-protein adducts were determined by
BCA protein assay (39) and the ratios of iso[4]LGE2-pyrrole to
protein were calculated (Table I).
Lactam, and Hydroxylactam Epitopes in LGE2-Protein Ad-
ducts—Studies detailed elsewhere (19), employing mass spec-
tral detection of lipid-modified lysine to characterize epitopes
generated by covalent adduction of LGE2 with proteins, uncov-
ered oxidative modifications that append one or two atoms of
oxygen to protein-bound LGE2-derived pyrroles. Thus, while
LGE2-lysine adduct containing the expected lysine-LGE2-pyr-
role could be prepared if oxygen is rigorously excluded, expo-
sure to air or enzymatic proteolysis of LGE2-protein adduct
produced only mono- and dioxygenated lysine-LGE2-pyrrole.
These oxidized pyrroles almost certainly are lactams and hy-
droxylactams (Fig. 6) generated by well known free radical-
initiated reactions of molecular oxygen with electron-rich pyr-
roles (45, 46).
These oxidized derivatives of LGE2-pyrrole cross-react
strongly with LGE2-KLH antibodies. Thus, a sample contain-
ing a mixture of lysine-LGE2-lactam and lysine-LGE2-hydroxy-
lactam was isolated by HPLC from a Paal-Knorr condensation
of LGE2 with radiolabeled lysine and subsequent oxidation by
adventitous oxygen. Quantitative radiochemical analysis in
conjunction with an ELISA comparison of binding with LGE2-
KLH antibodies, showed 256% cross-reactivity for the hydroxy-
lactam-lactam mixture relative to the LGE2-HSA standard.
Specificity of LGE2- and Iso[4]LGE2-KLH Antibodies—Struc-
tural specificities were also examined for the LGE2-KLH and
iso[4]LGE2-KLH antibodies to selectively recognize the LGE2-
HSA and iso[4]LGE2-HSA standards, respectively. ELISA
binding inhibition studies for cross-reactivity of iso[4]LGE2-
KLH antibody (Fig. 7) and LGE2-KLH antibody (Fig. 8) with
various haptens demonstrated excellent specificity for both
antibodies. Thus, neither antibody recognizes a protein-bound
FIG. 6. Oxidative conversion of LGE2-pyrrole into lactam and
hydroxylactam derivatives.
FIG. 7. Inhibition curves showing cross-reactivity of
iso[4]LGE2-KLH antibody for iso[4]LGE2-HSA (l), 4-oxopen-
tanal-BSA (), LGE2-HSA (E), LDL (M), and HSA (f) against
iso[4]LGE2-BSA as coating agent.
FIG. 8. Inhibition curves showing cross-reactivity of LGE2-
KLH antibody for iso[4]LGE2-HSA (E), 4-oxopentanal-BSA (),
LGE2-HSA (l), LDL (M), and HSA (f) against LGE2-BSA as coat-
ing agent.
TABLE I
Ehrlich pyrrole assay of iso[4]LGE2-protein adducts
Sample Protein byBCA assay
Protein lysyla
groups Iso[4]LGE2 added
Pyrrole by
Ehrlich assay Pyrrole/protein Pyrrole/protein
mg mmol mmol mmol mmol/mg mol/mol
Iso[4]LGE2
-BSA 11.1 9.86 3.69 3.54 6 1.29 0.32 21 6 8
Iso[4]LGE2
-KLH 6.25 3.13 4.54 2.62 6 0.32 0.42 1257 6 153
Iso[4]LGE2
-HSA 18.1 16.1 7.10 8.26 6 0.19 0.46 30 6 1
a The molecular weight (43) of KLH is taken to be 3 3 106 and number of lysyl residues in KLH, determined by TNBS assay, is 0.5 mmol/mg (44).
For both BSA (FW 5 66,430) and HSA (FW 66,437) the number of lysyl groups were calculated using the value of 59 mol of Lys/mol of protein.
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2-methylpyrrole, 4-oxopentanal-BSA (36), that lacks prostan-
oid or isoprostanoid side chains. The data presented in Table II
establish that each of these antibodies shows outstandingly low
cross-reactivity toward protein adducts of the structurally iso-
meric levulinaldehyde derivative. Thus, the LGE2-KLH anti-
bodies bind LGE2-HSA 200 times more strongly than they bind
iso[4]LGE2-HSA, while the iso[4]LGE2-KLH antibodies bind
iso[4]LGE2-HSA at least 2000 times more strongly than they
bind LGE2-HSA. Furthermore, cross-reactivity of either anti-
body toward HSA, native LDL, or HSA adducts of (E)-4-hy-
droxy-2-nonenal (HNE) or malondialdehyde (MDA) was not
detected.
Generation of LGE2-HSA and Iso[4]LGE2-HSA Immunoreac-
tivity by Fe21-catalyzed Oxidation of AA but Not Linoleic Acid
(LA) or Docosahexaenoic Acid (DHA)—In vitro free radical ox-
idations of a variety of PUFAs with iron and ascorbate were
performed in the presence of HSA. Immunoreactive protein-
bound epitopes were detected by ELISAs with LGE2-KLH (Fig.
9) and iso[4]LGE2-KLH (Fig. 10) antibodies in the reaction
product mixture from AA but not in the reaction product mix-
ture from LA. Similar experiments with g-linolenic (g-LA),
DHA, ETA, and EPA acids revealed the generation of protein
epitopes that cross-react with LGE2-KLH and iso[4]LGE2-KLH
antibodies from g-LA, ETA, and EPA, but not DHA (see below).
LGE2-Protein and Iso[4]LGE2-Protein Adduct Immunoreac-
tivity in OxLDL—LDL was oxidized by dialyzing an aqueous
solution of LDL in air against a buffer containing Cu21, an in
vitro model (2) for physiological oxidation of LDL. Oxidation
was halted after various time periods by sequestration of Cu21
with Na2EDTA added to an aliquot of the reaction mixture.
After an induction period, during which the endogenous anti-
oxidants presumably were consumed, immunoreactivity to-
ward both LGE2-KLH (Fig. 11) and iso[4]LGE2-KLH (Fig. 12)
antibodies increased rapidly, reaching a plateau after several
hours. The immunoreactivity detected for LGE2-protein and
iso[4]LGE2-protein epitopes in the oxLDL corresponded to a
final ratio of 1:4, respectively.
Free LGE2 Is Not Present in OxLDL—A trapping ELISA was
used detect any free LGE2 that might be present in the reaction
product mixture generated by in vitro oxidation of LDL in the
presence of Cu21. Free LGE2 can be trapped by the protein
coating agent (BSA) to give immunoreactive LGE2-pyrrole
epitope. Thus, a linear increase in absorbance was found for
increasing concentrations of free LGE2 (see Fig. 5). However,
the wells treated with ultrafiltrate from oxLDL showed no
absorbance, indicating that they contained no free LGE2.
DISCUSSION
IsoLGs—The chemistry of LDL oxidation is quite complex. A
plethora of lipid oxidation products is generated, and some of
these covalently modify LDL protein, apolipoprotein (apo) B (3,
4). Two aldehydic fragmentation products, MDA and HNE,
have been studied extensively because they form adducts with
apoB, and because the MDA-LDL (47) and HNE-LDL (48)
adducts could be atherogenic, in contrast with native LDL.
Besides protein-bound HNE, free HNE is detectable in oxLDL.
In a recent study, free HNE was quantitatively analyzed by an
“HNE-trapping ELISA” based on the detection of epitopes gen-
erated when HNE is trapped by a protein that has been coated
FIG. 9. Inhibition curves for binding of anti-LGE2-KLH to
LGE2-BSA by LGE2-HSA standard (l), LGE2-HSA generated dur-
ing the oxidation of AA (), but not LA (), in the presence of
HSA.
FIG. 10. Inhibition curves for binding of anti-iso[4]LGE2-KLH
to iso[4]LGE2-BSA by iso[4]LGE2-HSA standard (l), iso[4]LGE2-
HSA generated during the oxidation of AA (D), but not LA (), in
the presence of HSA.
FIG. 11. Generation of LGE2-protein adducts by oxidation of
LDL (0.5 mg/ml) with Cu21 (10 mM).
TABLE II
LGE2-KLH and Iso[4]LGE2-KLH antibody specificity
Antibody Coating LGE2-KLH LGE2-BSA Iso[4]LGE2-KLH Iso[4]LGE2-BSA
Protein or epitope IC50 Cross-reactivity IC50 Cross-reactivity
pmol/well % pmol/well %
LGE2-HSA 4.85 100 845 0.5
Iso[4]LGE2-HSA 10,000 ,0.1 4.2 100
Native LDL or HSA NDb ND ND ND
HNE-HSAa ND ND 8172 ,0.1
HNE-HSA-reduceda ND ND 13087 ,0.1
MDA-HSAa ND ND ND ND
a Prepared as described previously (38).
b ND, not detected.
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onto an immunoplate (49). This study demonstrated that a
considerable amount of free HNE is released from human
plasma LDL upon Cu21-promoted oxidation. In contrast, em-
ploying an analogous LGE2-trapping-ELISA, we now find no
evidence for the presence of free LGE2 in LDL that has under-
gone Cu21-promoted oxidation. This is expected because, as we
have noted elsewhere (8, 19), LGE2 binds with proteins far
more avidly than HNE. There is a physiological steady-state
concentration of free HNE in human venous blood plasma (50,
51). In contrast, the generation of LGs and iso[n]LGs in vivo
must be inferred from detection of protein-bound derivatives.
Studies employing the new iso[4]LGE2-KLH antibodies to de-
tect iso[4]LGE2-derived protein epitopes in vivo are in progress.
Preliminary results show that these protein modifications are
present in human blood plasma, confirming the hypothesis that
a family of levulinaldehyde derivatives is generated in vivo by
a free radical-induced oxidation of AA-PC (Fig. 13). Thus, non-
regioselective hydrogen atom abstraction from the 7, 10, and 13
positions of an arachidonyl ester produces three regioisomeric
pentadienyl radicals. These then react with molecular oxygen
to afford four regioisomeric peroxyeicosatetraenoyl radicals
that undergo peroxy radical cyclization (28, 52) to deliver four
structurally isomeric endoperoxides. Besides the geometrically
enforced cis relationship of the endoperoxide oxygens and a
preference for peroxy radical cyclization to produce stereoiso-
mers with cis disposed side chains (28), each structurally iso-
meric endoperoxide is expected to be generated as a mixture of
16 stereoisomers that are referred to collectively as isoPGH2 or
iso[n]PGH2 where [n] specifies the number of carbon atoms in
the carboxyl side chain of the non-prostanoid structural iso-
mers. Each endoperoxide rearranges to form two structurally
isomeric isoLGs or iso[n]LGs, designated as E series if the
acetyl substituent is nearer than the formyl substituent to the
carboxyl group or as D series if the formyl is nearer than the
acetyl to the carboxyl.
Paal-Knorr condensation of the eight structurally isomeric
FIG. 12. Generation of iso[4]LGE2-protein adducts by oxida-
tion of LDL (0.5 mg/ml) with Cu21 (10 mM).
FIG. 13. The iso[n]LG cascade of le-
vulinaldehyde derivatives generated
by free radical-induced oxidation of
AA-PC.
Protein Adducts of Iso[4]levuglandin E2 20277
 by guest on January 16, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
isoLGs and iso[n]LGs with protein primary amino groups pro-
duces eight different pyrrole epitopes. We previously reported
chemical evidence for the initial formation of pyrroles that
incorporate the e-amino group of protein lysyl residues (15).
Our recent studies employing mass spectral detection of lipid-
modified lysine uncovered the facile oxidation of LGE2-derived
pyrroles leading to lactam and hydroxylactam derivatives, and
confirmed that isoLG-derived lysyl group modifications are
present in oxLDL (19). Those studies also demonstrated the
formation of LGD2 epimers in the free radical-induced oxida-
tion of AA. Since LGD2-protein and LGE2-protein adducts can
be produced by the enzymatic COX pathway, only detection of
iso[n]LG-protein adducts, i.e. with nonprostanoid side chains,
can provide unambiguous evidence for the operation in vivo of
the free radical-promoted oxidative pathway summarized in
Fig. 13. We now have two orthogonal polyclonal rabbit antibod-
ies, i.e. that recognize and strongly discriminate between,
LGE2-protein and iso[4]LGE2-protein adducts.
As expected, LGE2-protein and iso[4]LGE2-protein immuno-
reactivity are produced by free radical oxidation of AA but not
LA, the most abundant polyunsaturated fatty acid in LDL. We
now have a panel of five antibodies that specifically detect
epitopes produced by the adduction of different lipid oxidation
products with proteins (Table III). In the reaction product
mixture from in vitro oxidation of AA in the presence of HSA,
pyrrole epitopes derived from HNE and 5-hydroxy-8-oxo-6-oc-
tenoic acid (HOOA) were detected previously. HNE-pyrrole was
also detected in the reaction product mixture from in vitro
oxidation of LA in the presence of HSA. On the other hand,
pyrrole epitopes derived from 9-hydroxy-12-oxo-10-dodecenoic
acid (HODA) are a selective marker for LA oxidation in the
presence of protein.
HNE-pyrrole epitope (detected with ON-KLH antibody) was
generated in the oxidation of v-6 but not v-3 PUFAs in the
presence of HSA. Thus, the v-6 acids LA, g-LA, AA, and ETA
all afforded immunoreactivity detectable with ON-KLH anti-
bodies while the v-3 acids DHA and EPA did not (Table IV).
Although LA and AA are the major PUFAs in normal human
serum phospholipids, oxidative cleavage of ETA in vivo may
produce significant amounts of HNE.
Oxidation of g-LA, ETA, and EPA in the presence of HSA
produces protein epitopes that cross-react with LGE2-KLH and
iso[4]LGE2-KLH antibodies. The levels of ETA and EPA in
human LDL vary greatly with diet (Table IV) and, therefore,
the LDL from some individuals can contain levels of these
PUFAs that may contribute significantly to the generation of
LGE2-KLH or iso[4]LGE2-KLH immunoreactivity. The selec-
tive generation of iso[4]LGE2-KLH immunoreactivity from
g-LA, LGE2-KLH immunoreactivity from ETA, and both LGE2-
KLH and iso[4]LGE2-KLH immunoreactivity from EPA (Table
IV) is a reasonable consequence of the fact that only a close
structural analogue of iso[4]LGE2 is expected to be generated
upon oxidation of g-LA, a LGE2 analogue upon oxidation of
ETA, and analogues of both iso[4]LGE2 and LGE2 upon oxida-
tion of EPA (Fig. 14).
LGE2 and Iso[4]LGE2 Epitope Families—Owing to concerns
that LG-derived protein-bound pyrroles would be readily mod-
ified by oxidation, our earliest efforts to detect LGE2-derived
protein epitopes immunologically relied upon cross-reactivity
of those epitopes with antibodies raised against a stable pyr-
azole isostere-derived antigen (53). Quite unexpectedly, the
immunoreactivity generated by the reaction of LGE2 with pro-
teins showed no decrease over several weeks. While this could
be the result of some stabilizing influence of the protein matrix
on an otherwise readily oxidizable pyrrole hapten, we recog-
nized the possibility of an alternative explanation. Thus, if the
molecular fragment responsible for antibody recognition is pre-
served in secondary products derived from the initially formed
pyrroles, e.g. the corresponding lactam or hydroxylactam (Fig.
6), in particular two prostanoid side chains appended to neigh-
boring sp2 carbons on a five-membered ring, then large changes
in antibody binding need not accompany transformations of the
LGE2-pyrrole into these secondary products. Thus, in contrast
with the excellent discrimination for variations in the side
chains appended to the pyrrole ring at positions 3 and 4, both
the LGE2-KLH and iso[4]LGE2-KLH antibodies could show a
high tolerance for modifications at the 2 and 5 positions of the
pyrrole ring. Furthermore, the LGE2-pyrrole and iso[4]LGE2-
pyrrole antigens most probably were oxidized after administra-
tion to rabbits, and therefore, some or all of the LGE2-KLH and
iso[4]LGE2-KLH antibodies in the polyclonal mixtures were
raised against lactam or hydroxylactam epitopes. Since the
side chains on the pyrrole, lactam, and hydroxylactam epitopes
are appended to coplanar sp2-hybridized carbons, they are re-
stricted to the same coplanar geometry. This conformational
rigidity is probably responsible for the excellent discrimination
by LGE2-KLH and iso[4]LGE2-KLH antibodies for LGE2- and
iso[4]LGE2-derived haptens, respectively. Thus, although the
functionality in the side chains of LGE2- and iso[4]LGE2-pro-
tein adducts is the same, the different lengths of the side chains
TABLE III
Oxidation of LA or AA in the presence of HSA
LA (7.13 mmol) or AA (6.6 mmol) and HSA (0.45 mmol) in pH 7.4 PBS
(0.1 M) were incubated at 37 °C in the presence of ascorbate (0.9 mM)
and FeSO4 (37 mM) for 24 h under air.
Antibody
Immunoreactivity (pmol/ml) Hapten,
Protein
adductLA oxidation AA oxidation
LGE2-KLH ND
a (2) 313 (1) LGE2-pyrrole
Iso[4]LGE2-KLH ND (2) 475 (1) IsoLGE2-pyrrole
DODA-KLH 44 (1) ND (2) HODA-pyrrole
DOOA-KLH ND (2) 2 (1) HOOA-pyrrole
ON-KLH 276 (1) 390 (1) HNE-pyrrole
c ND, not detected.
TABLE IV
Immunoreactivity (% of value for AA) generated by oxidation of PUFAs in the presence of HSA
PUFA (2.0 mg) and HSA (0.45 mmol) in pH 7.4 PBS (0.1 M, 10 ml) were incubated 24 h at 37 °C in the presence of FeSO4 (37 mM) and ascorbate
(0.9 mM) under air. Immunoreactivity is relative to HSA-iso[4]LGE2, HSA-LGE2, and HSA-ON standards.
PUFA
Antibody Composition
Iso[4]LGE2-KLH LGE2-KLH ON-KLH LDL
a Serumb
LA NDa ND 71 17 (19.6) 22.9
g-LA 23 ND 37 0.1
Docosahexaenoic ND ND ND 2.7 (4.8) 2.2
AA 100 100 100 4.8 (7.1) 11.0
ETA ND 23 14 10 (1.4) 3.1
EPA 17 16 ND 0.9 (5.6) 0.7
a Weight percent in LDL phospholipids calculated from data for individuals on a corn oil (fish oil) diet (56).
b Weight percent in normal human serum phospholipids (20).
c ND, not detected.
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and restriction of conformational possibilities for their disposi-
tion results in strong but geometrically different interactions of
the polar functional groups in each side chain with the respec-
tive antibodies.
Quantitative Analysis of LGE2 and Iso[4]LGE2—Previously,
we used quantitative radiochemical analysis to accurately de-
termine the amount of LGE2 contained in protein adduct stand-
ards. Because radiolabeled iso[4]LGE2 is not presently avail-
able, we had to employ a less direct method to determine the
amount of iso[4]LGE2-derived pyrrole present in the
iso[4]LGE2-KLH antigen, iso[4]LGE2-BSA coating agent, and
iso[4]LGE2-HSA standard. While the Ehrlich assay is not sen-
sitive enough to detect the low concentrations of iso[4]LGE2-
derived pyrroles present in human blood or generated upon
oxidation of LDL, it was feasible to use this assay to compare
the concentrations of LGE2-derived and iso[4]LGE2-derived
pyrroles in the protein adducts prepared as standards. The
iso[4]LGE2 to protein ratios, i.e. 21, 30 and 1257 mol/mol,
calculated for the BSA, HSA, and KLH adducts, are higher
than found previously for analogous LGE2-protein adducts, i.e.
10.5, 11.9, and 951 mol/mol of BSA, HSA, and KLH (21). Fur-
thermore, in an earlier study, when BSA was exposed to a large
excess (125 equivalents) of tritium-labeled LGE2, one molecule
of BSA was found to bind a maximum of about 16 molecules of
LGE2 (14). It seems reasonable to expect that a similar limit
would apply to binding of iso[4]LGE2, Especially important is
the concentration of iso[4]LGE2-pyrrole determined for
iso[4]LGE2-HSA because this standard was used to calculate
the amount of iso[4]LGE2-pyrrole in oxLDL samples. The 30:1
ratio determined indirectly by Ehrlich assay for iso[4]LGE2-
HSA seems to overestimate the actual levels by factor of two.
The concentrations of iso[4]LGE2-protein adduct indicated in
the figures and tables must be interpreted in light of this
caveat.
Possible Etiological Importance of LGs and Iso[n]LGs in
Artheriosclerosis—With mouse peritoneal macrophages, we
previously showed that the covalent adduct of LGE2 with hu-
man LDL (LGE2-LDL) is internalized and degraded if the mo-
lar ratio of LGE2 to LDL protein, apoB, exceeds a threshold
somewhere between 10:1 and 38:1 (8). OxLDL, but not acetyl-
LDL that is recognized by the prototypical scavenger receptor,
efficiently competed for receptor binding and uptake of LGE2-
LDL. This result suggests that LGE2-LDL was recognized by a
class of scavenger receptor that demonstrated ligand specificity
for oxLDL but not for acetyl-LDL. However, our previous study
of LDL oxidation found that only 1–2 mol of LGE2-protein
adduct are generated per mole of apoB (27). Nevertheless, it
is reasonable to anticipate that macrophage recognition of
iso[n]LG-LDLs will be similar to that of LGE2-LDL, and that
total levels of LG and iso[n]LG protein adducts in oxLDL are
sufficient to account for the recognition and uptake of oxLDL by
human monocyte-macrophages in the arterial wall, a key step
in the etiology of atherosclerosis. Thus, substantial evidence
now suggests that atherosclerotic plaques form when mono-
cytes are recruited into the arterial intima to become macro-
phages where they grow into bloated, lipid-laden foam cells by
accumulating large amounts of oxLDL (1, 9, 54).
Studies on the localization of immunoreactive LG-protein
and iso[4]LG-protein epitopes in human atherosclerotic
plaques are in progress in our laboratories. The details of these
studies will be reported in due course. Since deficient process-
ing of oxLDL in macrophages leads to foam cell formation, it is
especially noteworthy that processing of LGE2-LDL exhibits an
inefficiency similar to that found for oxLDL and, therefore, that
incompletely processed LGE2-LDL accumulates in macro-
phages (8). The resistance to lysozomal degradation of oxLDL
which accumulates in macrophages may be a consequence of
continued oxidative modification or aggregation of the particles
which occurs following uptake (55). In this regard, it is espe-
cially pertinent that LGE2 binds avidly (within minutes) with
proteins (14), and the reaction of LGE2 with proteins generates
reactive electrophilic intermediates that are responsible for a
slower process, protein-protein cross-linking (14, 17). In other
words, LG- and iso[n]LG-protein adducts are expected to be
“sticky,” readily forming protein-protein cross-links by binding
to additional protein-based nucleophiles. It is tempting to spec-
ulate that such cross-links with proteolytic enzymes interfere
with processing of oxLDL.
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